@inproceedings{inproceedings, title  = {{1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles}},

 publisher = {{Elsevier BV}},

 url = {{}},

 year = {{2014}},

 month = {{9}},

 author = {{Parker C and Vogelzang N and Sartor O and Bottomley D and Coleman RE and Skjorestad I and Aksnes A and Wahba M and Nilsson S}},

 doi = {{10.1093/annonc/mdu336.17}},

 volume = {{25}},

 journal = {{Annals of Oncology}},

 pages = {{iv263-iv263}},

 note = {{Accessed on 2025/10/10}}}